Bryce B Reeve1, Sandra A Mitchell2, Amylou C Dueck2, Ethan Basch2, David Cella2, Carolyn Miller Reilly2, Lori M Minasian2, Andrea M Denicoff2, Ann M O'Mara2, Michael J Fisch2, Cynthia Chauhan2, Neil K Aaronson2, Corneel Coens2, Deborah Watkins Bruner2. 1. Affiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BBR, EB); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (SAM); Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (LMM and AMO); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (AMD); Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ (ACD); Feinberg School of Medicine, Northwestern University, Chicago, IL (DC); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (CMR, DWB); Department of General Oncology, MD Anderson Cancer Center, Houston, TX (MJF); Mayo Clinic Breast SPORE, Rochester, MN (CCh); Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands (NKA); Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium (CCo). bbreeve@email.unc.edu. 2. Affiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BBR, EB); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (SAM); Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (LMM and AMO); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (AMD); Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ (ACD); Feinberg School of Medicine, Northwestern University, Chicago, IL (DC); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (CMR, DWB); Department of General Oncology, MD Anderson Cancer Center, Houston, TX (MJF); Mayo Clinic Breast SPORE, Rochester, MN (CCh); Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands (NKA); Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium (CCo).
Abstract
BACKGROUND: The National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee held a clinical trials planning meeting (September 2011) to identify a core symptom set to be assessed across oncology trials for the purposes of better understanding treatment efficacy and toxicity and to facilitate cross-study comparisons. We report the results of an evidence-synthesis and consensus-building effort that culminated in recommendations for core symptoms to be measured in adult cancer clinical trials that include a patient-reported outcome (PRO). METHODS: We used a data-driven, consensus-building process. A panel of experts, including patient representatives, conducted a systematic review of the literature (2001-2011) and analyzed six large datasets. Results were reviewed at a multistakeholder meeting, and a final set was derived emphasizing symptom prevalence across diverse cancer populations, impact on health outcomes and quality of life, and attribution to either disease or anticancer treatment. RESULTS: We recommend that a core set of 12 symptoms--specifically fatigue, insomnia, pain, anorexia (appetite loss), dyspnea, cognitive problems, anxiety (includes worry), nausea, depression (includes sadness), sensory neuropathy, constipation, and diarrhea--be considered for inclusion in clinical trials where a PRO is measured. Inclusion of symptoms and other patient-reported endpoints should be well justified, hypothesis driven, and meaningful to patients. CONCLUSIONS: This core set will promote consistent assessment of common and clinically relevant disease- and treatment-related symptoms across cancer trials. As such, it provides a foundation to support data harmonization and continued efforts to enhance measurement of patient-centered outcomes in cancer clinical trials and observational studies.
BACKGROUND: The National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee held a clinical trials planning meeting (September 2011) to identify a core symptom set to be assessed across oncology trials for the purposes of better understanding treatment efficacy and toxicity and to facilitate cross-study comparisons. We report the results of an evidence-synthesis and consensus-building effort that culminated in recommendations for core symptoms to be measured in adult cancer clinical trials that include a patient-reported outcome (PRO). METHODS: We used a data-driven, consensus-building process. A panel of experts, including patient representatives, conducted a systematic review of the literature (2001-2011) and analyzed six large datasets. Results were reviewed at a multistakeholder meeting, and a final set was derived emphasizing symptom prevalence across diverse cancer populations, impact on health outcomes and quality of life, and attribution to either disease or anticancer treatment. RESULTS: We recommend that a core set of 12 symptoms--specifically fatigue, insomnia, pain, anorexia (appetite loss), dyspnea, cognitive problems, anxiety (includes worry), nausea, depression (includes sadness), sensory neuropathy, constipation, and diarrhea--be considered for inclusion in clinical trials where a PRO is measured. Inclusion of symptoms and other patient-reported endpoints should be well justified, hypothesis driven, and meaningful to patients. CONCLUSIONS: This core set will promote consistent assessment of common and clinically relevant disease- and treatment-related symptoms across cancer trials. As such, it provides a foundation to support data harmonization and continued efforts to enhance measurement of patient-centered outcomes in cancer clinical trials and observational studies.
Authors: Frederick J Meyers; John Linder; Laurel Beckett; Scott Christensen; Joan Blais; David R Gandara Journal: J Pain Symptom Manage Date: 2004-12 Impact factor: 3.612
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Bhishamjit S Chera; Avraham Eisbruch; Barbara A Murphy; John A Ridge; Patrick Gavin; Bryce B Reeve; Deborah Watkins Bruner; Benjamin Movsas Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Danielle B Tometich; Catherine E Mosher; Adam T Hirsh; Kevin L Rand; Shelley A Johns; Marianne S Matthias; Samantha D Outcalt; Bryan P Schneider; Lida Mina; Anna Maria V Storniolo; Erin V Newton; Kathy D Miller Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603
Authors: Larissa A Meyer; Alpa M Nick; Qiuling Shi; Xin Shelley Wang; Loretta Williams; Tremaine Brock; Maria D Iniesta; Kelly Rangel; Karen H Lu; Pedro T Ramirez Journal: Gynecol Oncol Date: 2015-01-31 Impact factor: 5.482
Authors: Aparna Mitra; Greyson Willis Grossman Biegert; Andrea Y Delgado; Tatiana V Karpinets; Travis N Solley; Melissa P Mezzari; Kyoko Yoshida-Court; Joe F Petrosino; Megan D Mikkelson; Lilie Lin; Patricia Eifel; Jianhua Zhang; Lois M Ramondetta; Anuja Jhingran; Travis T Sims; Kathleen Schmeler; Pablo Okhuysen; Lauren E Colbert; Ann H Klopp Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-25 Impact factor: 7.038
Authors: Angela M Stover; Benjamin Y Urick; Allison M Deal; Randall Teal; Maihan B Vu; Jessica Carda-Auten; Jennifer Jansen; Arlene E Chung; Antonia V Bennett; Anne Chiang; Charles Cleeland; Yehuda Deutsch; Edmund Tai; Dylan Zylla; Loretta A Williams; Collette Pitzen; Claire Snyder; Bryce Reeve; Tenbroeck Smith; Kristen McNiff; David Cella; Michael N Neuss; Robert Miller; Thomas M Atkinson; Patricia A Spears; Mary Lou Smith; Cindy Geoghegan; Ethan M Basch Journal: JCO Oncol Pract Date: 2020-02-19
Authors: Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina A Acquaye; Mark R Gilbert; Harshad Ladha; Tito Mendoza Journal: Neuro Oncol Date: 2015-08-19 Impact factor: 12.300